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Abstract: Development of a new improved and efficient process suitable  for the large-scale production of 
Irbesartan has been described.  The key steps are tetrazole formation from secondary amide for the preparation 
of  the  key  intermediate  1-Benzyl-5-(4'-bromomethyl-biphenyl-2-yl)-1H-tetrazole  (9),  N-alkylation  and 
debenzylation. 
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1. Introduction 
 
Irbesartan 1 is a non-peptide angiotensin II receptor antagonist used in the management of 
hypertension,  heart  diseases,  heart  strokes,  diabetic  neuropathy  and  congestive  heart  diseases.
1 
Irbesartan is currently available in the market as an antihypertensive drug under the brand name of 
Avapro.
2  The  metabolism  of  Irbesartan,  a  highly  selective  and  potent  nonpeptide  angiotensin  II 
receptor antagonist, has been investigated
 in humans.
3 Irbesartan inhibits the activity of angiotensin II 
(AII) via specific, selective noncompetitive antagonism of the AII receptor subtype 1 (AT1) which 
mediates most of the known physiological activities of AII.
4  
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To  meet  the  Irbesartan  drug  demand  of  the  market,  there  is  a  need  to  develop  an  ideal 
commercial  process,  which  is  a  safe,  ecologically  sound,  economic  and  meets  the  quality 
specifications. The first reported synthetic method 
5, 6 for the preparation of Irbesartan as shown in 
Scheme 1
 consists of the condensation of 4'-Bromomethyl-biphenyl-2-carbonitrile (2) with 2-butyl-
1,3-diaza-spiro[4,4]non-1-en-4-one  hydrochloride  (3)  using  sodium  hydride  (NaH)  as  a  base  and 
dimethyl formamide (DMF) as solvent medium. The second step involves the tetrazole formation by 
treating tributyltinazide in xylene followed by trityl protection to obtain Trityl Irbesartan. The trityl 
group was cleaved by treating with aqueous hydrochloride in methanol and tetrahydrofuran mixture.  
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Scheme 1. Reagents and conditions: (a) NaH, DMF, rt, 1 h, 79%. (b) tributyltin azide, xylene, reflux, 
66 h, trityl chloride, 26 h, 72%. (c) 4N HCl, methanol, THF, rt, 4 h, 67%.  
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  This process suffers from the disadvantages such as (a) NaH is used as base in the first step of 
the process for which utmost care should be taken to perform the reaction under inert atmosphere as it 
is  an  exothermic  reaction,  highly  sensitive  towards  moisture,  it  is  unsafe  and  not  suitable  for 
production on commercial scale (b) The purification of the compound 4 and compound 5 was done 
through column chromatography which is not commercially viable (c) Tri-n-butyltinazide was used as 
reagent for the tetrazole formation in the step 2. Toxicity of tin in humans is most frequently reported 
as the exposure to tin compounds will cause memory loss and insomnia as well as other symptoms 
like  death.
7  Neurotoxicity  and  liver  damage  has  been  reported  with  tin  compounds  exposure  in 
humans.
8 Considering the toxic effects of tin, this route is not suitable for the preparation of Irbesartan 
with respect to safety and health aspects (d) The temperature for the tetrazole formation step is high 
and the time cycle is more i.e. reflux in xylene (~150
oC) for 66 hours which is not a economic and 
ecofriendly process (e) The tetrazole group was protected by tritylation using trityl chloride. As the 
deprotection of the trityl group in the final step will give trityl alcohol as byproduct which is the 
potential impurity in this process and it is not removed easily (e) The over yield of the process is 38% 
only. Our quest to develop a more economic and cost effective process for important API`s prompted 
us to develop an efficient process for Irbesartan. 
In the present communication, we report the preparation of Irbesartan using 1-benzyl-5-(4'-
bromomethyl-biphenyl-2-yl)-1H-tetrazole  (9)  which  has  provided  an  advantage  in  improving  the 
overall yield (66%) and also circumvented the repeated column chromatographic purifications.  
 
2. Results and Discussion 
Our  research  work  focuses  on  the  design  of  a  new  commercially  viable  process  for  the 
preparation of Irbesartan. Based on the literature search, we developed a five stage process which 
involves  the  preparation  of  the  key  intermediate,  1-Benzyl-5-(4'-bromomethyl-biphenyl-2-yl)-1H-
tetrazole (9) starting from 4'-Methyl-biphenyl-2-carboxylic acid (6) and the subsequent condensation 
with  2-Butyl-1,3-diaza-spiro[4.4]non-1-en-4-one  hydrochloride  (3)  and  insitu  debenzylation  of  the 
intermediate compound 10 to provide Irbesartan (1) (Scheme 2) in excellent yield as illustrated below, 
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Scheme 2. Reagents and conditions: (a) SOCl2, TEA, toluene, 20-25
oC, 2 h. (b) benzylamine, 20-
25
oC,  4h,  95%  for  two  steps.  (c)  triphenylphosphine  /  diethyl  azodicarboxylilate  (DEAD)  / 
trimethylsilylcyanide, THF, 20-25
oC, 24 h, 91%. (d) DBDMH, AIBN, EtOAc, reflux, 6 h, 89%. (e) Rao and Babu., Org. Commun. (2011) 4:4 105-111 
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KOH, acetone, 25-30
oC, 2 h. (f) 5% Pd/C, ammonium formate, isopropanol, water, 50-55
oC, 15 h, 
85% for two steps.  
Accordingly, our first priority was to prepare the key intermediate 9. There are some prior art 
procedures available in the literature for the preparation compounds 8 and 9 
9, 10, which involves the 
use  of  organo  transition  metals  and  harsh  conditions  and  the  yields  reported  are  low.  We  have 
identified 4'-Methyl-biphenyl-2-carboxylic acid (6) as the starting material for the preparation of the 
key intermediate 9. Compound 6 is treated with thionyl chloride to form acid chloride followed by the 
reaction with benzylamine to afford the amide compound 7 in 95% yield. We have screened different 
solvents  and bases  for  the  transformation  of  compound 6  to compound 7.  Optimum results were 
observed when triethylamine used as base in combination with toluene as solvent. The next task was 
the tetrazole formation from the amide compound 7, which was a challenging part of the synthesis. 
There are few methods reported in the literature for the preparation of 1,5-substituted tetrazoles from 
secondary  amides.
11-13  Initially  we  attempted  the  tetrazole  formation  using  phosphorous 
pentachloride/sodium azide. This is a two step process, which involves the imidoyl chloride formation 
by the reaction of amide compound 7 with PCl5 in dichloromethane followed by the reaction with 
NaN3 in DMF to afford the tetrazole product. The yield of the product obtained as low in this method 
and it was also observed that the dehydration of the amide was taking place concurrently to form the 
compound  4  as  an  impurity.  Later,  we  used  triphenylphosphine/diethyl  azodicaroxylate  (DEAD)/ 
trimethylsilylazide  ((CH3)3SiN3)  for  the  construction  of  tetrazole  ring  from  compound  7.  The 
transformation was clean and product obtained in high yield (91%) under these mild conditions.  
After successful optimization of the tetrazole ring formation, the compound 8 is subjected to benzylic 
bromination using 1,3-dibromo-5,5-dimethylhydantoin (DBDMH) in ethylacetate medium and 2,2’-
azobis(2-methylpropionitrile) (AIBN) as free radical initiator to furnish the key intermediate 9 in 89% 
yield (Scheme 2). DBDMH was observed to be suitable brominating reagent among other reagents 
tried for this transformation. 
The compound 9 is reacted with the spiro compound 3 in the presence of potassium hydroxide 
in acetone medium to afford the benzyl protected Irbesartan as a residue which is directly proceeded 
to debenzylation without isolation. The debenzylation was performed using 5% palladium over carbon 
and ammonium formate in isopropanol and water mixture to afford Irbesartan in 90% yield. Before we 
arrived at the final conditions of the debenzylation, other methods were attempted like hydrogenation 
using  Pd/C  under  H2  pressure,  Pd/C  with  formic  acid.  These  methods  were  observed  to  be  low 
yielding.  
In summary, an improved and efficient approach to the preparation of Irbesartan has been 
developed  by  employing  the  condensation  of  the  key  intermediate  1-benzyl-5-(4'-bromomethyl-
biphenyl-2-yl)-1H-tetrazole  (9)  with  2-butyl-1,3-diaza-spiro[4.4]non-1-en-4-one  hydrochloride  (3) 
followed by the debenzylation.  
Our process has the advantages like (a) toxic metal compounds such as tri-n-butyl tin azide are 
not used in the formation of tetrazole ring (b) hazardous reagents like sodium hydride are avoided for 
the condensation reaction (c) column chromatographic purifications are not required in any stage (d) 
the use of protecting groups which will give to the byproducts that can arise as impurities in the 
finished product are avoided (e) the overall yield of the process is high (66%) when compared to the 
reported synthesis (38%). 
 
3.Conclusion 
In  conclusion,  we  have  developed  a  new  improved,  inexpensive  and  industrially  scalable 
process for the synthesis of the anti hypertensive drug Irbesartan, which can provide high throughputs 
and high quality product in each stage. 
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4.  Experimental  
 
4.1. General Procedures 
 
 All  solvents  and  reagents  were  purchased  from  the  commercial  suppliers  and  used  without 
further purification. All non-aqueous reactions were performed in dry glassware under an atmosphere 
of  dry  nitrogen.  Organic  solutions  were  concentrated  under  reduced  pressure.  Thin  layer 
chromatography  (TLC)  was  performed  on  Merck  precoated  Silica-gel  60F254  plates.  The  NMR 
spectra were recorded in DMSO at 400 MHz on a Varian Gemini 200 MHz FT-NMR spectrometer. 
The chemical shifts were reported in δ ppm relative to TMS. The FT-IR spectra were recorded in the 
solid  state  as  KBr  dispersion  using  a  Perkin-Elmer  1650  FT-IR  spectrophotometer.  The  mass 
spectrum (70 eV) was recorded on an Agilent-6310 LC-MS spectrometer. The elemental analysis was 
carried out using Elementar Vario Micro analyzer.  
 
4.2. Preparation of 4'-Methyl-biphenyl-2-carboxylic acid benzylamide (7) 
 
To  a  stirred  solution  of  4'-Methyl-biphenyl-2-carboxylic  acid  (6)  (100g,  0.471  moles)  in 
toluene  (500  mL)  was  added  triethylamine  (3.0  mL)  and  cooled  the  contents  to  0-5
oC.  Thionyl 
chloride (58.8 g, 0.494 moles) was added slowly drop-wise during 10-15 minutes by maintaining the 
internal temperature 0-5
oC. The reaction mixture was slowly allowed to reach 20-25
oC and stirred for 
2  hours  at  same  temperature.  The  contents  were  cooled  to  0-5
oC  and  added  benzylamine  
(55.7 g, 0.52 moles) slowly drop-wise during 20-25 minutes. The reaction mixture was allowed to 
reach 20-25
oC and maintained for 4 hours. Once the completion of the reaction is confirmed by TLC, 
the reaction mass was further diluted with toluene (300 mL) and added water (500mL) slowly to the 
reaction mass by keeping the temperature below 30
oC. The contents were stirred for 10-15 minutes at 
25-30
oC and the organic phase is separated. The aqueous phase is further extracted with toluene (200 
mL) and the combined organic layer was washed with saturated NaHCO3 solution (50 mL) followed 
by water (50 mL). The organic phase was separated, dried over Na2SO4 (5.0g) and the solvent was 
distilled off completely under reduced pressure. To the residue, diisopropylether (100 mL) was added 
and again distilled completely to remove the traces of ethylacetate. Finally diisopropylether (200 mL) 
was added and stirred the contents for 30-45 minutes at 20-25
oC followed by maintenance for 30-45 
minutes at 0-5
oC. The compound was filtered and washed with precooled diisopropylether (50 mL). 
The wet cake was dried under vacuum at 45-50
oC for 8 hours to obtain compound 7 as off-white solid.   
Yield:  135.3  g  (95.3%).  Purity  by  HPLC:  99.2%,  m.p:  145
oC,  IR  (KBr,  cm
-1)  3293  
(-NH), 1648 (C=O); 
1H NMR (DMSO-d6): δ 7.75-7.72 (dd, 1H, J=7.6 Hz, J=1.2 Hz),7.48-7.26 (m, 
5H), 7.24-7.15(m, 5H), 6.90-6.87(m, 2H), 5.45(s, 1H, exchanged with D2O), 4.34(d, 2H, J=6.0 Hz), 
2.39(s,  3H); 
13C-NMR  (DMSO-d6):168.4,  142.1,  137.1,  135.9,  133.0,  132.5,  129.5,  128.1,  127.4, 
127.9, 127.1,126.8, 126.1, 51.2, 23.2; MS (m/z): 302.3[M
++1]; Anal. Calcd for C21H19NO: C, 83.69; 
H, 6.35; N, 4.65. Found: C, 83.67; H, 6.30; N, 4.64. 
 
4.3. Preparation of 1-Benzyl-5-(4'-methyl-biphenyl-2-yl)-1H-tetrazole (8) 
 
To a stirred solution of compound 7 (125g, 0.415 moles) in tetrahydrofuran (625 mL) was 
added  Triphenylphosphine  (161.8  g,  0.617  moles)  under  Nitrogen  atmosphere.  Diethylazo-
dicarboxylate  (98.8  g,  0.617  moles)  was  added  slowly  drop  wise  at  below  20
oC  and  stirred  the 
contents at 20-25
oC for 45 minutes. Trimethylsilylazide (71.1g, 0.617 moles) was added slowly drop 
wise and the reaction mixture was maintained at 20-25
oC for 24 hours. The completion of the reaction 
was assessed by TLC and the reaction mass was diluted with ethyl acetate (1500mL)) and washed 
with  saturated  sodium  bicarbonate  solution followed  by  water  wash.  The  ethyl  acetate  layer  was 
separated and dried over sodium sulfate. The solvent was evaporated under reduced pressure and the 
obtained residue was crystallized from ethyl acetate and n-hexane mixture to afford compound 8 as 
off-white crystalline solid.  Yield: 123.5 g (91.2%), Purity by HPLC: 98.6%, m.p: 137
oC, 
1H NMR Rao and Babu., Org. Commun. (2011) 4:4 105-111 
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(DMSO-d6): δ 7.74-7.70 (dd, 1H, J=7.6 Hz, J=1.6 Hz), 7.59-7.50 (m, 3H), 7.27-7.19 (m, 3H), 7.09-
7.08 (d, 2H, J=7.6 Hz), 6.89-6.87 (d, 2H, J=8.0 Hz), 6.80-6.79 (d, 2H, J=6.4 Hz), 5.08 (2H, s), 2.28 
(3H, s); 
13C-NMR (DMSO-d6): δ 152.5, 137.5, 136.4, 135.6, 135.2, 133.7, 129.4, 129.3, 128.1,127.7, 
127.4, 127.5, 125.2, 49.2, 21.7; MS (m/z): 327.2 [M
++1]; Anal. Calcd for C21H18N4: C, 77.28; H, 5.56; 
N, 17.17. Found: C, 77.23; H, 5.51; N, 17.14. 
 
4.3. Preparation of 1-Benzyl-5-(4'-bromomethyl-biphenyl-2-yl)-1H-tetrazole (9) 
 
To a stirred solution of compound 8 (120 g, 0.368 moles) in ethylacetate (480 mL) was added 
DBDMH (71.5 g, 0.250 moles) and stirred for 10-15 minutes at 20-25
oC. Added AIBN (1.2 g, 0.007 
moles) to the reaction mixture and the contents were refluxed for 6 hours. After the completion of the 
reaction, the contents were cooled to 20-25
oC and added water (250 mL). The contents were stirred at 
same temperature for 20-30 minutes. The organic phase was separated and washed with saturated 
sodium bicarbonate solution (150 mL) followed by water (150 mL) and dried over anhydrous sodium 
sulphate (6.0 g). The solvent was evaporated completely under reduced pressure to afford compound 9 
as a semi solid. Yield: 133.8g (89.7 %). Purity by HPLC: 98.1%; 
1H NMR (DMSO-d6): δ 7.76-7.72 (t, 
1H, J=7.4 Hz), 7.76-7.48 (m, 3H), 7.44-733 (m, 2H), 7.25-7.18(m, 3H), 7.01-6.92 (m, 2H), 6.81 (d, 
2H, J=6.82 Hz), 5.14(s, 2H), 4.68 (s, 2H); 
13C-NMR(DMSO-d6): δ 152.1, 139.7, 137.1, 136.5, 135.2, 
134.4, 129.5, 129.1, 128.9, 128.1, 127.7, 127.5, 127.3, 124.1, 47.2, 36.4; MS (m/z): 405.3 [M
+]; Anal. 
Calcd for C21H17BrN4: C, 62.23; H, 4.23; Br, 19.72; N, 13.82. Found: C, 62.18; H, 4.20; N, 13.78. 
 
4.4. Preparation of 2-Butyl-3-[2'-(1H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-1,3-diaza-spiro [4.4]non-1-
en-4-one  (1) 
 
To a stirred solution of 2-Butyl-1,3-diaza-spiro[4.4]non-1-en-4-one hydrochloride (3) (74.7 g, 
0.324 moles)  in acetone (625 mL) was added potassium hydroxide (69 g, 1.232 moles) at below 30
oC. 
The  contents  were  stirred  for  30-45  minutes  at  25-30
oC  was  added  1-Benzyl-5-(4'-bromomethyl-
biphenyl-2-yl)-1H-tetrazole (9) (125 g, 0.308 moles) portion wise and stirred for 2 hours at 25-30
oC. 
The completion of the reaction can be monitored by TLC. The salts were filtered off, washed with 
acetone (50 mL) and the filtrate was completely distilled off under reduced pressure to obtain 3-[2'-(1-
Benzyl-1H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-2-butyl-1,3-diaza-spiro[4.4]non-1-en-4-one  (10)  as  a 
residue. This compound was dissolved in mixture of methanol (435 mL) and water (275 mL). Added 
palladium carbon (15 g, 5% wet), ammonium formate (73.7 g, 1.17 moles), the resultant reaction 
mixture was heated to 50-55
oC and stirred for 15 hours. The reaction completion is confirmed by TLC 
and the reaction mass was filtered through celite and washed with methanol (75 mL). The filtrate was 
distilled off completely under reduced pressure to obtain crude product, which was recrystallized from 
isopropanol to obtain Irbesartan 1 as a white solid. Yield: 112.7 g (85.3 %). Purity by HPLC: 99.6 %, 
m.p:181-182
oC, IR (KBr, cm
-1) 1732 (C=O), 1616 (C=N); 
1H NMR (DMSO-d6): δ 7.95–7.32 (m, 8 
H), 4.80 –4.60 (s, 2 H), 3.60– 3.00 (br s, 1 H), 2.40– 2.20 (t, 2 H , J = 6.04 Hz), 2.00– 1.60 (m, 8 
H),1.60–1.45 (quint, 2 H), 1.40– 1.20 (sext, 2 H), 0.91–0.70 (t, 3H, J = 7.41 Hz); 
13C-NMR (DMSO-
d6): δ 186.5, 162.0,155.9, 141.9, 139.2, 137.2. 131.9, 131.4, 130.1, 128.7, 127.1, 124.3, 76.7, 43.1, 
37.7, 28.3, 27.4, 26.3, 22.4, 14.5; MS: m/z= 429 [M+1]; Anal. Calcd for C25H28N6O : C, 70.07; H, 
6.59; N, 19.61. Found: C, 70.04; H, 6.57; N, 19.58. 
 
3-[2'-(1-Benzyl-1H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-2-butyl-1,3-diaza-spiro[4.4]non-1-en-4-
one (10). 
1H NMR (DMSO d6): δ 7.74(d, 1H, J=7.2 Hz), 7.62(t, 1H, J=6.8 Hz), 7.54 (t, 1H, J=7.2 Hz), 
7.46(d, 1H, J=7.6 Hz), 7.39-7.37(m, 3H), 7.18-7.16(m, 2H), 7.08-7.02(m, 4H), 5.82(s, 2H), 4.68(s, 
2H), 2.28(t, 2H, J=7.6 Hz), 1.85-1.83(m, 6H), 1.68-1.66(m, 2H), 1.50-1.41(m, 2H), 1.27-1.21(m, 2H), 
0.77(t, 3H, J=7.2 Hz); MS (m/z): 519.2 [M
++1]. 
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